Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
Clinical trial NCT02423200 · COMPLETED
Trial details
- NCT number
- NCT02423200
- Sponsor
- EIP Pharma Inc
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-01
- Primary completion
- 2016-09-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.